£20bn promised to NHS but questions over where money will come from

pharmafile | June 18, 2018 | News story | Medical Communications, Sales and Marketing NHS, UK government, biotech, drugs, pharma, pharmaceutical 

Theresa May finally attempted to tackle the elephant in the room for the UK government, well, the one other than progression of Brexit discussions, by pledging that the NHS would receive a funding boost of £20 billion per year.

The amount promised by May amounts to an increase in spending of 3.4% on the NHS annually, after a period under the coalition government where funding was limited to 1.1% increases and then rises averaging 2.3% under the Conservative government.

May communicated to the public through her Facebook page the news and revealed that the money would arrive from a “Brexit dividend” but that signalled that further contribution would likely be needed from the public. In her statement, she wrote: “Now, as we leave the European Union and stop paying significant annual subscriptions to Brussels, we will have more money to spend on priorities like the NHS.

“But to give the NHS the funding it needs for the future, this Brexit dividend will not be enough. As a country, we need to contribute a bit more in a fair and balanced way. We will listen to views about how we do this and the Chancellor will set out the detail in due course.”

Immediately after May made the announcement, a raft of criticism arrived that there would be no such Brexit dividend. Even Conservative MP, Sarah Wollaston who chairs the Commons Health and Social Care committee, tweeted on the news:  “The Brexit dividend tosh was expected but treats the public as fools. Sad to see Govt slide to populist arguments rather than evidence on such an important issue. This will make it harder to have a rational debate about the ‘who & how’ of funding & sharing this fairly.”

The reason the Brexit dividend statement has taken such a hammering is that, by many estimates, there will be no short-term increases to Government coffers due to Brexit.

The government will still be paying membership payments until 2028, as part of the “divorce bill”, but has also agreed to continue providing funds in certain areas, such as agriculture and universities to retain certain benefits of EU membership.

According to The institute for Fiscal Studies, this will leave nothing extra to fund the NHS and points towards significant changes to taxes to make up the shortfall.

Ben Hargreaves

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content